[HTML][HTML] Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody
G Pacchiana, C Chiriaco, MC Stella… - Journal of biological …, 2010 - ASBMB
Met, the high affinity receptor for hepatocyte growth factor, is one of the most frequently
activated tyrosine kinases in human cancer and a validated target for cancer therapy. We
previously developed a mouse monoclonal antibody directed against the extracellular
portion of Met (DN-30) that induces Met proteolytic cleavage (receptor" shedding") followed
by proteasome-mediated receptor degradation. This translates into inhibition of hepatocyte
growth factor/Met-mediated biological activities. However, DN-30 binding to Met also results …
activated tyrosine kinases in human cancer and a validated target for cancer therapy. We
previously developed a mouse monoclonal antibody directed against the extracellular
portion of Met (DN-30) that induces Met proteolytic cleavage (receptor" shedding") followed
by proteasome-mediated receptor degradation. This translates into inhibition of hepatocyte
growth factor/Met-mediated biological activities. However, DN-30 binding to Met also results …